Li Jing, Chen Xi, Jiang Shibo, Chen Ying-Hua
Laboratory of Immunology, Department of Biology, Tsinghua University, Beijing 100084, PR China; Beijing Key Laboratory for Protein Therapeutics, Beijing 100084, PR China.
Biochem Biophys Res Commun. 2008 Nov 7;376(1):60-4. doi: 10.1016/j.bbrc.2008.08.105. Epub 2008 Aug 30.
The human monoclonal antibody 4E10 against the membrane-proximal external region (MPER) of HIV-1 gp41 demonstrates broad neutralizing activity across various strains, and makes its epitope an attractive target for HIV-1 vaccine development. Although the contiguous epitope of 4E10 has been identified, attempts to re-elicit 4E10-like antibodies have failed, possibly due to the lack of proper conformation of the 4E10 epitope. Here we used pIg-tail expression system to construct a panel of eukaryotic cell-surface expression plasmids encoding the extracellular domain of gp41 with deletion of fusion peptide and/or introduction of L568P mutation that may disrupt the gp41 six-helix bundle core conformation as DNA vaccines for immunization of mice. We found that these changes resulted in significant increase of the antigenicity and immunogenicity of 4E10 epitope. This information is thus useful for rational design of vaccines targeting the HIV-1 gp41 MPER.
针对HIV-1 gp41膜近端外部区域(MPER)的人源单克隆抗体4E10对多种毒株均表现出广泛的中和活性,使其表位成为HIV-1疫苗开发的一个有吸引力的靶点。尽管4E10的连续表位已被确定,但重新引发产生4E10样抗体的尝试均告失败,这可能是由于缺乏4E10表位的正确构象。在此,我们使用pIg-尾表达系统构建了一组真核细胞表面表达质粒,这些质粒编码缺失融合肽和/或引入L568P突变的gp41胞外结构域,该突变可能会破坏gp41六螺旋束核心构象,作为用于免疫小鼠的DNA疫苗。我们发现这些变化导致4E10表位的抗原性和免疫原性显著增加。因此,该信息有助于合理设计针对HIV-1 gp41 MPER的疫苗。